
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
BNTX | NASDAQ | USD | Real-time | |
BNTXN | BIVA | MXN | Delayed | |
22UAy | Xetra | EUR | Delayed | |
22UAy | Frankfurt | EUR | Delayed | |
22UAy | TradeGate | EUR | Delayed | |
BNTX | Vienna | EUR | Real-time |
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Name | Age | Since | Title |
---|---|---|---|
Helmut W. Jeggle | 51 | 2008 | Independent Supervisory Board Chairman |
Ulrich Wandschneider | 61 | 2018 | Independent Deputy Chairman Supervisory Board |
Rolf M. Zinkernagel | 79 | - | Member of Scientific Advisory Board |
Michael Motschmann | 66 | 2008 | Independent Supervisory Board Member |
Hans Hengartner | 79 | - | Member of Scientific Advisory Board |
Nicola Blackwood | 44 | 2023 | Member of Supervisory Board |
Anja Morawietz | 46 | 2022 | Supervisory Board Member |
Rudolf Staudigl | 69 | 2022 | Supervisory Board Member |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review